Literature DB >> 31499027

Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis.

Corey M Porter1, Michael C Haffner1, Ibrahim Kulac1, Janielle P Maynard1, Javier A Baena-Del Valle1, William B Isaacs2, Srinivasan Yegnasubramanian3, Angelo M De Marzo4, Karen S Sfanos5.   

Abstract

Lactoferrin (LTF) is an iron-binding protein canonically known for its innate and adaptive immune functions. LTF may also act as a tumor suppressor with antiproliferative action. LTF is inactivated genetically or epigenetically in various cancers, and a CpG island spanning the transcriptional start site of LTF is hypermethylated in prostate cancer cell lines. We, therefore, hypothesized that LTF expression is silenced via CpG island hypermethylation in the early stages of prostate tumorigenesis carcinogenesis. Targeted methylation analysis was performed using a combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes, and laser-capture microdissection followed by bisulfite sequencing on DNA isolated from prostate tissue samples, including both primary and metastatic disease. LTF mRNA in situ hybridization and LTF protein immunohistochemistry were also performed. We report that the LTF CpG island is frequently and densely methylated in high-grade prostatic intraepithelial neoplasia, primary prostate carcinoma, and metastases. We further report a decoupling of lactoferrin mRNA and protein expression, including in lesions where LTF mRNA has presumably been silenced via CpG island methylation. We conclude that LTF mRNA expression is silenced in prostate tumorigenesis via hypermethylation, supporting a role for LTF as a prostate cancer tumor suppressor gene. Likewise, the frequency at which the LTF CpG island is methylated across samples suggests it is an important and conserved step in prostate cancer initiation.
Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31499027      PMCID: PMC6892185          DOI: 10.1016/j.ajpath.2019.07.016

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Detection of exon polymorphisms in the human lactoferrin gene.

Authors:  Li-Herng Eric Liu; Wesley Gladwell; Christina T Teng
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

Review 2.  Overview of Lactoferrin as a Natural Immune Modulator.

Authors:  Dominique Legrand
Journal:  J Pediatr       Date:  2016-06       Impact factor: 4.406

3.  Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.

Authors:  Geert J L H van Leenders; Wesley R Gage; Jessica L Hicks; Bianca van Balken; Tilly W Aalders; Jack A Schalken; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals.

Authors:  H Tsuda; K Sekine; N Takasuka; H Toriyama-Baba; M Iigo
Journal:  Biofactors       Date:  2000       Impact factor: 6.113

Review 5.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

6.  Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells.

Authors:  Dominique Legrand; Keveen Vigié; Elias A Said; Elisabeth Elass; Maryse Masson; Marie-Christine Slomianny; Mathieu Carpentier; Jean-Paul Briand; Joël Mazurier; Ara G Hovanessian
Journal:  Eur J Biochem       Date:  2004-01

7.  Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine.

Authors:  Masaaki Iigo; David B Alexander; Ne Long; Jiegou Xu; Katsumi Fukamachi; Mitsuru Futakuchi; Mitsunori Takase; Hiroyuki Tsuda
Journal:  Biochimie       Date:  2008-06-27       Impact factor: 4.079

Review 8.  Lactoferrin in a Context of Inflammation-Induced Pathology.

Authors:  Marian L Kruzel; Michal Zimecki; Jeffrey K Actor
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

Review 9.  Iron in the Tumor Microenvironment-Connecting the Dots.

Authors:  Christa Pfeifhofer-Obermair; Piotr Tymoszuk; Verena Petzer; Günter Weiss; Manfred Nairz
Journal:  Front Oncol       Date:  2018-11-26       Impact factor: 6.244

10.  Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma.

Authors:  Chanbora Chea; Mutsumi Miyauchi; Toshihiro Inubushi; Nurina Febriyanti Ayuningtyas; Ajiravudh Subarnbhesaj; Phuong Thao Nguyen; Madhu Shrestha; Sivmeng Haing; Kouji Ohta; Takashi Takata
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

View more
  4 in total

1.  Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.

Authors:  Kaushal Asrani; Alba Fc Torres; Juhyung Woo; Thiago Vidotto; Harrison K Tsai; Jun Luo; Eva Corey; Brian Hanratty; Ilsa Coleman; Srinivasan Yegnasubramanian; Angelo M De Marzo; Peter S Nelson; Michael C Haffner; Tamara L Lotan
Journal:  J Pathol       Date:  2021-09-23       Impact factor: 7.996

2.  Differential gene methylation and expression of HOX transcription factor family in orbitofacial neurofibroma.

Authors:  Antje Arnold; Eddie Luidy Imada; M Lisa Zhang; Deepak P Edward; Luigi Marchionni; Fausto J Rodriguez
Journal:  Acta Neuropathol Commun       Date:  2020-05-04       Impact factor: 7.801

3.  Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma.

Authors:  Rujia Qin; Chunyan Li; Xuemin Wang; Zhaoming Zhong; Chuanzheng Sun
Journal:  Cancer Cell Int       Date:  2021-07-15       Impact factor: 5.722

Review 4.  Health inequity drives disease biology to create disparities in prostate cancer outcomes.

Authors:  William G Nelson; Otis W Brawley; William B Isaacs; Elizabeth A Platz; Srinivasan Yegnasubramanian; Karen S Sfanos; Tamara L Lotan; Angelo M De Marzo
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.